Financing ·
MDxHealth SA reported second quarter 2026 revenue of $27.2 million, a 16% increase year-over-year and a $3.3 million…
MDXHMDxHealth SA
MDxHealth SA reported second quarter 2026 revenue of $27.2 million, a 16% increase year-over-year and a $3.3 million sequential rise from Q1. The company maintained its full-year 2026 revenue guidance of $110-115 million. Operating loss widened to $5.1 million due to expenses from the ExoDx acquisition, resulting in a net loss of $9.5 million and negative adjusted EBITDA of $(2.3) million. Concurrently, MDxHealth executed a registered direct placement of 44,052,862 ordinary shares at $0.454 per share, raising $20 million in gross proceeds to strengthen its balance sheet. The firm also finalized the wind-down of its discontinued Resolve mdx business through an Assignment for the Benefit of Creditors. MDxHealth SA operates in the precision diagnostics industry, providing molecular tests for prostate cancer and urologic diseases.